FY2026 EPS Forecast for Xeris Biopharma Increased by Analyst

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Equities researchers at HC Wainwright upped their FY2026 EPS estimates for Xeris Biopharma in a research note issued on Friday, November 6th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.14 per share for the year, up from their previous estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.07 per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q4 2026 earnings at $0.06 EPS, FY2027 earnings at $0.13 EPS and FY2030 earnings at $1.03 EPS.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $107.23 million for the quarter, compared to analysts’ expectations of $101.68 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%.

Several other research firms have also commented on XERS. Barclays upped their price target on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, October 6th. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday. Oppenheimer restated an “outperform” rating and set a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a research report on Friday. Piper Sandler restated a “neutral” rating and set a $12.00 target price (up from $8.00) on shares of Xeris Biopharma in a research report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, November 4th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.20.

Xeris Biopharma Price Performance

Shares of XERS opened at $15.86 on Tuesday. The firm has a market cap of $2.89 billion, a PE ratio of -317.14 and a beta of 0.61. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The firm has a fifty day simple moving average of $9.77 and a two-hundred day simple moving average of $7.66. Xeris Biopharma has a 1-year low of $5.25 and a 1-year high of $15.94.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Beth Hecht sold 25,000 shares of Xeris Biopharma stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $255,750.00. Following the completion of the transaction, the insider directly owned 1,086,130 shares of the company’s stock, valued at $11,111,109.90. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $51,150.00. Following the transaction, the insider owned 1,346,053 shares in the company, valued at $13,770,122.19. This trade represents a 0.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 173,332 shares of company stock valued at $1,721,471 over the last three months. 4.35% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds have recently added to or reduced their stakes in XERS. Chicago Partners Investment Group LLC grew its position in Xeris Biopharma by 16.3% in the third quarter. Chicago Partners Investment Group LLC now owns 13,286 shares of the company’s stock worth $136,000 after buying an additional 1,861 shares during the last quarter. AlphaCentric Advisors LLC lifted its position in shares of Xeris Biopharma by 4.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock valued at $464,000 after acquiring an additional 1,940 shares during the last quarter. Allworth Financial LP boosted its stake in shares of Xeris Biopharma by 86.4% during the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after acquiring an additional 2,000 shares in the last quarter. Jacksonville Wealth Management LLC grew its holdings in shares of Xeris Biopharma by 11.8% in the 3rd quarter. Jacksonville Wealth Management LLC now owns 19,000 shares of the company’s stock worth $182,000 after acquiring an additional 2,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Xeris Biopharma by 7.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 33,266 shares of the company’s stock worth $332,000 after acquiring an additional 2,190 shares during the last quarter. 42.75% of the stock is currently owned by institutional investors.

Trending Headlines about Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for FY2026 to $0.14 from $0.04, FY2027 to $0.13 from $0.11, and FY2030 to $1.03 from $0.92. The firm reiterated its Buy rating and $18 price target. Xeris analyst estimates
• Positive Sentiment: Wall Street Zen upgraded Xeris, while Oppenheimer reiterated its Outperform rating; another report says the consensus brokerage view is Moderate Buy. Wall Street Zen upgrade Brokerage consensus Oppenheimer rating
• Neutral Sentiment: Piper Sandler reiterated a Neutral rating, tempering the otherwise positive analyst commentary. Piper Sandler rating

Xeris Biopharma Company Profile

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative.

The company also develops drug-delivery technologies intended to make medicines easier to store and administer.